Midodrine
Adrenergic and Dopaminergic Agents
- Drug class
- Adrenergic and Dopaminergic Agents
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 30
Overview
Plain-language summary, compiled from the cited regulatory records
Midodrine is a medication classified as an adrenergic and dopaminergic agent [1]. It is approved for the treatment of symptomatic orthostatic hypotension (OH) [1]. Orthostatic hypotension is a condition characterized by a drop in blood pressure upon standing, leading to symptoms.
Midodrine hydrochloride tablets are intended for patients whose daily lives are significantly impacted by OH, even after trying standard treatments. These standard treatments may include non-pharmacologic approaches like wearing support stockings, increasing fluid intake, and making lifestyle adjustments [1]. The use of midodrine is considered when these measures are insufficient to manage the condition [1].
This medication is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 23 | May 29, 2026 |
| US United States | FDA | 5 | July 15, 2025 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
GBUnited Kingdom· MHRA
23 products
Uses
Bramox 5 mg tablets are indicated in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.
How to take
USUnited States· FDA
5 products
Uses
INDICATIONS AND USAGE
Midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure (BP>200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations.
The indication is based on midodrine’s effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to perform life activities, have not been established.
Further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets. After initiation of treatment, midodrine hydrochloride tablets should be continued only for patients who report significant symptomatic improvement.
CACanada· Health Canada
2 products
Uses
AND CLINICAL USE .......................................................................................... 3 CONTRAINDICATIONS ................................................................................................................
4 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS ................................................................................................................
6 DRUG INTERACTIONS ............................................................................................................... 12 DOSAGE AND ADMINISTRATION...........................................................................................
12 OVERDOSAGE ............................................................................................................................. 13 ACTION AND CLINICAL PHARMACOLOGY .........................................................................
Drug interactions
Known interactions involving Midodrine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL415420002 · revised November 22, 2024
- [2]FDA DailyMed · 03b54024-2a26-4a… · revised January 27, 2023 [PDF]
- [3]Health Canada (DPD) · 02533200 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.